Management of New Mild Patchy Opacities

Immediate Clinical Assessment

The American Thoracic Society recommends determining whether new mild patchy opacities represent active disease requiring intervention or stable chronic changes, by assessing medication history, exposure history, smoking status, temporal pattern, and autoimmune symptoms 1, 2, 3, 4, 5, 6
A systematic exposure and medication history is crucial to exclude drug-related pneumonitis and hypersensitivity pneumonitis, with specific inquiry about molecular targeting agents, immune checkpoint inhibitors, amiodarone, methotrexate, and nitrofurantoin 2, 1, 3, 4
Current or former smokers may have respiratory bronchiolitis-ILD or desquamative interstitial pneumonia, both presenting with patchy opacities and having a better prognosis than idiopathic pulmonary fibrosis 5, 4, 3

The American College of Radiology recommends that the distribution and characteristics of patchy opacities guide the differential diagnosis, with peripheral and lower lobe predominant patterns suggesting organizing pneumonia, early idiopathic pulmonary fibrosis, or connective tissue disease-related ILD 6, 5, 4
A centrilobular distribution indicates respiratory bronchiolitis-ILD in smokers, hypersensitivity pneumonitis, or pulmonary veno-occlusive disease 7, 8, 5, 4

The American Thoracic Society recommends obtaining baseline pulmonary function tests, including spirometry with DLCO, to establish baseline lung function and detect subclinical restriction or gas exchange impairment 1
High-resolution CT characterization is mandatory for proper characterization of interstitial lung disease, with assessment of ground-glass opacity extent, honeycombing, and traction bronchiectasis 1, 5, 4, 3

The European Respiratory Society recommends that if drug-related pneumonitis is suspected, management depends on CT pattern, with organizing pneumonia pattern responding to corticosteroids with drug dose reduction, and diffuse alveolar damage pattern requiring immediate drug discontinuation and high-dose corticosteroids 2, 3
For asymptomatic patients with stable-appearing changes, a conservative approach with repeat HRCT in 6-12 months to assess for progression is appropriate 1

The American College of Chest Physicians recommends not diagnosing IPF without systematically excluding hypersensitivity pneumonitis, and not dismissing patchy opacities as "just atelectasis" without confirming absence of traction bronchiectasis or honeycombing 1
HRCT is mandatory for proper characterization of interstitial lung disease, and not relying on chest radiograph findings alone 1

The American Thoracic Society recommends considering surgical lung biopsy if HRCT pattern is indeterminate and clinical suspicion for progressive ILD is high, or if clinical and radiologic findings do not clearly indicate a specific pattern 1, 3